FDA declines to approve Regeneron’s linvoseltamab amid manufacturing issues – Pharmaceutical Technology
Regeneron submitted the biologics licence application (BLA) for linvoseltamab to the FDA under priority review in February this year. Image credit: Shutterstock / lev radin.